Junshi Biosciences Posts Strong Revenue Growth on Toripalimab Sales
Event summary
- Junshi Biosciences reported RMB2,498 million in total revenue for 2025, a 28% increase from 2024, driven by toripalimab sales.
- R&D expenses rose 9% to RMB1,384 million as the company expanded its drug pipeline and accelerated clinical trials.
- Net cash inflow from financing activities was RMB2,232 million, with a successful H-share placing generating RMB940 million.
- Toripalimab gained multiple new approvals in China and internationally, including for NPC and ESCC treatments.
- Junshi Biosciences secured a distribution deal with LEO Pharma for toripalimab in Europe and the UK.
The big picture
Junshi Biosciences' strong financial performance underscores the growing demand for its core product, toripalimab, particularly in China. The company's strategic focus on expanding its drug pipeline and securing international approvals positions it to compete with global biopharmaceutical leaders. With a robust cash position and successful financing activities, Junshi Biosciences is well-equipped to fund its ambitious R&D initiatives.
What we're watching
- Pipeline Execution
- The pace at which Junshi Biosciences advances its diverse drug pipeline, including small molecule drugs and antibody-drug conjugates.
- Regulatory Momentum
- Whether the company can sustain its regulatory approvals for toripalimab in key international markets.
- Commercialization Strategy
- How Junshi Biosciences leverages its partnership with LEO Pharma to expand toripalimab's reach in Europe and the UK.
Related topics